| Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment J Spetz, J Moslehi, K Sarosiek Current treatment options in cardiovascular medicine 20, 1-11, 2018 | 92 | 2018 |
| Biodistribution and dosimetry of free 211At, 125I− and 131I− in rats J Spetz, N Rudqvist, E Forssell-Aronsson Cancer Biotherapy and Radiopharmaceuticals 28 (9), 657-664, 2013 | 90 | 2013 |
| Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity Z Inde, BA Croker, C Yapp, GN Joshi, J Spetz, C Fraser, X Qin, L Xu, ... Science Advances 7 (34), eabf8609, 2021 | 62 | 2021 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 46 | 2023 |
| T Cells and Regulated Cell Death: Kill or Be Killed J Spetz, AG Presser, KA Sarosiek International review of cell and molecular biology 342, 2018 | 45 | 2018 |
| Radionuclide therapy via SSTR: future aspects from experimental animal studies E Forssell-Aronsson, J Spetz, H Ahlman Neuroendocrinology 97 (1), 86-98, 2013 | 31 | 2013 |
| Hedgehog inhibitor sonidegib potentiates 177Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice J Spetz, B Langen, N Rudqvist, TZ Parris, K Helou, O Nilsson, ... BMC cancer 17, 1-11, 2017 | 30 | 2017 |
| Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2 J Dalmo, N Rudqvist, J Spetz, P Laverman, O Nilsson, H Ahlman, ... Oncology reports 27 (1), 174-181, 2012 | 27 | 2012 |
| Time-and dose rate-related effects of internal 177Lu exposure on gene expression in mouse kidney tissue E Schüler, N Rudqvist, TZ Parris, B Langen, J Spetz, K Helou, ... Nuclear medicine and biology 41 (10), 825-832, 2014 | 26 | 2014 |
| Priming increases the anti-tumor effect and therapeutic window of 177Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1 J Dalmo, J Spetz, M Montelius, B Langen, Y Arvidsson, H Johansson, ... EJNMMI research 7, 1-16, 2017 | 22 | 2017 |
| Transcriptional response in normal mouse tissues after i.v. 211At administration - response related to absorbed dose, dose rate, and time B Langen, N Rudqvist, TZ Parris, E Schüler, J Spetz, K Helou, ... EJNMMI research 5, 1-12, 2015 | 21 | 2015 |
| Transcriptional response to 131I exposure of rat thyroid gland N Rudqvist, J Spetz, E Schüler, TZ Parris, B Langen, K Helou, ... PLoS One 12 (2), e0171797, 2017 | 19 | 2017 |
| Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma–tools for choice of radionuclide therapy J Spetz, J Dalmo, O Nilsson, B Wängberg, H Ahlman, E Forssell-Aronsson Hormone and Metabolic Research 44 (05), 400-404, 2012 | 16 | 2012 |
| Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics VW Daniels, JJ Zoeller, N Van Gastel, KE McQueeney, S Parvin, ... Science signaling 14 (686), eabc7405, 2021 | 15 | 2021 |
| Gene expression signature in mouse thyroid tissue after 131I and 211At exposure N Rudqvist, J Spetz, E Schüler, B Langen, TZ Parris, K Helou, ... EJNMMI research 5, 1-14, 2015 | 14 | 2015 |
| Transcriptional Response in Mouse Thyroid Tissue after 211At Administration: Effects of Absorbed Dose, Initial Dose-Rate and Time after Administration N Rudqvist, J Spetz, E Schüler, TZ Parris, B Langen, K Helou, ... PloS one 10 (7), e0131686, 2015 | 14 | 2015 |
| Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure M Larsson, N Rudqvist, J Spetz, E Shubbar, TZ Parris, B Langen, K Helou, ... Plos one 15 (12), e0244098, 2020 | 11 | 2020 |
| Multiparametric MR for non‐invasive evaluation of tumour tissue histological characteristics after radionuclide therapy M Montelius, O Jalnefjord, J Spetz, O Nilsson, E Forssell‐Aronsson, ... NMR in Biomedicine 32 (3), e4060, 2019 | 11 | 2019 |
| Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after 177Lu [Lu]-octreotate therapy J Spetz, N Rudqvist, B Langen, TZ Parris, J Dalmo, E Schüler, ... Nuclear Medicine and Biology 60, 11-18, 2018 | 11 | 2018 |
| Identification of potential MR-derived biomarkers for tumor tissue response to 177Lu-octreotate therapy in an animal model of small intestine neuroendocrine tumor M Montelius, J Spetz, O Jalnefjord, E Berger, O Nilsson, M Ljungberg, ... Translational oncology 11 (2), 193-204, 2018 | 11 | 2018 |
Eva Forssell-AronssonProfessor of Medical Radiation Sciences, University of Gothenburg在 radfys.gu.se 的电子邮件经过验证
